A study published in the journal Lancet on Monday (Oct. 4) said that the COVID-19 vaccine was developed jointly by Pfizer and Biotech Effectiveness decreased to 47% after 2 injections for 6 months, down from the highest level of 88%.
However, the effectiveness of preventing hospitalization from illness is still as high as 90% if infected with different types of 2019 novel coronavirus. including delta type
This study was funded by Pfizer, Inc.
not only that This study also confirmed some of the earliest reports. from the US Centers for Disease Control and Prevention and the Israeli public health agency. that after several months The efficacy of the COVID-19 vaccine will decline, even if it continues to prevent infected people from getting sick from hospital.
The study comes less than two weeks after several U.S. health agencies approved the immunization of Pfizer and Biotech vaccines for older adults and adults at risk of contracting the virus. high leaven On the condition that these people had already received the Pfizer vaccine. no cross injection
A key advisory committee of the US Food and Drug Administration (FDA) will meet for two days next week. To discuss whether Modernna and Johnson & Johnson vaccinations should be vaccinated with immunizations.